Inclusion Criteria:

- Histologically or cytologically confirmed malignant pleural, peritoneal, or tunica
vaginalis mesothelioma

- Epithelial, sarcomatoid, or mixed subtype

- International Mesothelioma Interest Group stage II-IV disease (for patients with
pleural mesothelioma)

- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by
conventional techniques OR > 10 mm by spiral CT scan

- Pleural effusion and ascites are not considered measurable lesions

- Disease not amenable to curative surgery

- No known brain metastases

- ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100%

- Life expectancy > 3 months

- WBC ≥ 3,000/mm³

- Absolute neutrophil count ≥ 1,500/mm³

- Hemoglobin ≥ 8 g/dL

- Platelets ≥ 100,000/mm³

- Total bilirubin normal

- AST/ALT ≤ 2.5 times upper limit of normal(ULN)

- Creatinine normal OR creatinine clearance > 60 mL/min

- Fertile patients must use effective contraception

- Not pregnant or nursing

- Negative pregnancy test

- No history of allergic reactions to compounds of similar chemical or biologic
composition to AZD2171

- Mean QTc ≤ 500 msec (with Bazett's correction) by EKG

- No history of long QT syndrome

- Proteinuria ≤ 1+ on two consecutive dipsticks taken ≥ 1 week apart

- No other concurrent malignancy

- No New York Heart Association class III or IV cardiac disease

- No uncontrolled intercurrent illness including, but not limited to, any of the
following:

- Hypertension

- Ongoing or active infection

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- Psychiatric illness or social situations that would limit study compliance

- No more than 1 prior cytotoxic chemotherapy

- Prior intrapleural cytotoxic agents (including bleomycin) do not count towards
prior cytotoxic chemotherapy

- At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
and recovered

- No prior radiotherapy to the only site of measurable disease

- At least 4 weeks since prior radiotherapy and recovered

- At least 4 weeks since prior major surgery and recovered

- More than 30 days since prior participation in an investigational trial

- No prior treatment with a vascular endothelial growth factor (VEGF) inhibitor

- No other concurrent investigational agents

- No concurrent commercial agents for the malignancy

- No concurrent medication that may markedly affect renal function (e.g., vancomycin,
amphotericin, or pentamidine)

- No concurrent hematopoietic growth factors except epoetin alfa

- No concurrent palliative radiotherapy

- No combination antiretroviral therapy for HIV-positive patients

- No concurrent drugs or biologics with proarrhythmic potential